A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

BACKGROUND. Activation of the mitogen-activated protein kinase pathway is important for growth of pediatric low-grade gliomas (LGGs). The aim of this study was to determine the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumetinib in children with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Banerjee, Anuradha, Jakacki, Regina I., Onar-Thomas, Arzu, Wu, Shengjie, Nicolaides, Theodore, Young Poussaint, Tina, Fangusaro, Jason, Phillips, Joanna, Perry, Arie, Turner, David, Prados, Michael, Packer, Roger J., Qaddoumi, Ibrahim, Gururangan, Sridharan, Pollack, Ian F., Goldman, Stewart, Doyle, Lawrence A., Stewart, Clinton F., Boyett, James M., Kun, Larry E., Fouladi, Maryam
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570236/
https://ncbi.nlm.nih.gov/pubmed/28339824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars